{"id":"botulinum-toxin-intramuscular-injection","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Dry mouth"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Eyelid swelling"},{"rate":"5-10%","effect":"Drooping eyelid"},{"rate":"5-10%","effect":"Muscle weakness"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Dizziness"},{"rate":"5-10%","effect":"Pain"},{"rate":"5-10%","effect":"Injection site reaction"}]},"_chembl":{"chemblId":"CHEMBL4297862","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This is achieved by cleaving the SNARE complex, which is essential for the release of acetylcholine from the presynaptic neuron. As a result, muscle contractions are reduced, leading to a decrease in muscle spasms and contractions.","oneSentence":"Botulinum toxin works by blocking the release of acetylcholine, a neurotransmitter that transmits nerve impulses, thereby reducing muscle spasms and contractions.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:42:42.987Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of blepharospasm, hemifacial spasm, and strabismus"},{"name":"Treatment of cervical dystonia"},{"name":"Treatment of axillary hyperhidrosis"},{"name":"Treatment of facial wrinkles and frown lines"},{"name":"Treatment of migraines"},{"name":"Treatment of overactive bladder"}]},"trialDetails":[{"nctId":"NCT06783621","phase":"PHASE4","title":"A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVÉDERM® Products, KYBELLA, CoolSculpting Elite and SkinMedica Products","status":"COMPLETED","sponsor":"AbbVie","startDate":"2025-01-16","conditions":"Facial Contouring","enrollment":130},{"nctId":"NCT03992404","phase":"PHASE3","title":"Study to Compare the Efficacy and Safety of NT 201 (Botulinum Toxin) With Placebo for the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merz Pharmaceuticals GmbH","startDate":"2019-09-16","conditions":"Lower Limb or Combined Lower Limb and Upper Limb Spasticity Due to Stroke or Traumatic Brain Injury","enrollment":603},{"nctId":"NCT03198702","phase":"PHASE3","title":"Effectiveness and Safety of Early Intramuscular Botulinum Toxin Injections to Prevent Shoulder Deformity in Babies With Obstetrical Brachial Plexus Palsy","status":"RECRUITING","sponsor":"University Hospital, Brest","startDate":"2018-05-17","conditions":"Obstetrical Brachial Plexus Palsy","enrollment":62},{"nctId":"NCT06782464","phase":"NA","title":"Upper Limb Nerve Cryoneurolysis is Non Inferior to the Usual Care and Has Therapeutic Add Value in Dealing With Shoulder Pain and Functional Problems Caused by Spasticity and Motor Impairment","status":"RECRUITING","sponsor":"Centre National de Rééducation Fonctionnelle et de Réadaptation","startDate":"2024-12-12","conditions":"Hemiplegia, Spasticity, Shoulder Spasticity","enrollment":50},{"nctId":"NCT07478822","phase":"PHASE3","title":"A Study on Recombinant Botulinum Toxin Type A (YY001) for Injection in Multiple Treatments of Adult Upper Limb Spasticity","status":"RECRUITING","sponsor":"Chongqing Claruvis Pharmaceutical Co., Ltd.","startDate":"2026-03-20","conditions":"Upper Limb Spasticity","enrollment":300},{"nctId":"NCT07210463","phase":"PHASE3","title":"A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in Europe (PLATINUM EU)","status":"RECRUITING","sponsor":"Merz Aesthetics GmbH","startDate":"2025-10-01","conditions":"Neuromuscular Agents, Peripheral Nervous System Agents, Physiological Effects of Drugs","enrollment":300},{"nctId":"NCT06047457","phase":"PHASE3","title":"A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ipsen","startDate":"2023-09-29","conditions":"Episodic Migraine","enrollment":751},{"nctId":"NCT06047444","phase":"PHASE3","title":"A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ipsen","startDate":"2023-10-12","conditions":"Chronic Migraine","enrollment":759},{"nctId":"NCT07361900","phase":"PHASE1","title":"Management of Bruxism in Patients With Implant Overdenture","status":"COMPLETED","sponsor":"Delta University for Science and Technology","startDate":"2024-03-24","conditions":"Bruxism","enrollment":48},{"nctId":"NCT06783114","phase":"PHASE2, PHASE3","title":"A Clinical Study on Recombinant Botulinum Toxin Type A (YY001) for Injection in The Treatment of Upper Limb Spasticity in Adults","status":"RECRUITING","sponsor":"Chongqing Claruvis Pharmaceutical Co., Ltd.","startDate":"2024-09-14","conditions":"Upper Limb Spasticity","enrollment":254},{"nctId":"NCT05216250","phase":"PHASE2","title":"Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor","status":"COMPLETED","sponsor":"AbbVie","startDate":"2022-04-12","conditions":"Upper Limb Essential Tremor (UL ET)","enrollment":174},{"nctId":"NCT07331844","phase":"NA","title":"BTX-A and Mirror Therapy for Chronic Stroke Spasticity","status":"COMPLETED","sponsor":"Fatih Sultan Mehmet Training and Research Hospital","startDate":"2024-05-15","conditions":"Stroke, Spastic Hemiplegia","enrollment":30},{"nctId":"NCT06387394","phase":"PHASE3","title":"A Study to Assess BOTOX Injections in Adult Participants for the Change of Masseter Muscle Prominence","status":"COMPLETED","sponsor":"AbbVie","startDate":"2024-04-22","conditions":"Masseter Muscle Prominence","enrollment":202},{"nctId":"NCT06068855","phase":"PHASE3","title":"A Study to Assess the Effectiveness of BOTOX (Botulinum Toxin Type A) Injections for the Change of Masseter Muscle Prominence in Adult Participants","status":"COMPLETED","sponsor":"AbbVie","startDate":"2023-10-17","conditions":"Masseter Muscle Prominence","enrollment":249},{"nctId":"NCT05028569","phase":"PHASE3","title":"Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine","status":"TERMINATED","sponsor":"AbbVie","startDate":"2021-11-05","conditions":"Episodic Migraine","enrollment":775},{"nctId":"NCT07266064","phase":"NA","title":"Repeated Botulinum Toxin Type A Injections on Intramuscular Fat Accumulation in Individuals With Sleep Bruxism.","status":"COMPLETED","sponsor":"Melek Volkan Yazici","startDate":"2024-01-02","conditions":"Bruxism, Bruxism, Sleep, Bruxism, Sleep-Related","enrollment":27},{"nctId":"NCT06218251","phase":"PHASE4","title":"A Study to Evaluate Participant Satisfaction and Natural Outcomes Following Administration of BOTOX Cosmetic Injections in Adult Participants for Treatment of Upper Facial Lines","status":"COMPLETED","sponsor":"AbbVie","startDate":"2024-02-05","conditions":"Upper Facial Lines","enrollment":100},{"nctId":"NCT07236632","phase":"NA","title":"Hyaluronic Acid vs Botulinum Toxin Injection in Treatment of Lifelong Drug-Resistant Premature Ejaculation: Randomized Study","status":"NOT_YET_RECRUITING","sponsor":"Benha University","startDate":"2025-12-15","conditions":"Premature Ejaculation","enrollment":80},{"nctId":"NCT06399718","phase":"PHASE3","title":"A Study to Assess BOTOX Injections for the Change of Masseter Muscle Prominence in Adult Participants","status":"COMPLETED","sponsor":"AbbVie","startDate":"2024-04-30","conditions":"Masseter Muscle Prominence","enrollment":207},{"nctId":"NCT06834789","phase":"PHASE1","title":"A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2025-02-18","conditions":"Glabellar Lines","enrollment":132},{"nctId":"NCT07122193","phase":"PHASE3","title":"A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in the United States","status":"RECRUITING","sponsor":"Merz North America, Inc.","startDate":"2025-08-27","conditions":"Neuromuscular Agents, Peripheral Nervous System Agents, Physiological Effects of Drugs","enrollment":300},{"nctId":"NCT07180394","phase":"NA","title":"Botulinum Toxin for Strabismus Treatment","status":"NOT_YET_RECRUITING","sponsor":"Foundation University Islamabad","startDate":"2025-09-30","conditions":"Strabismic Deviation, Strabismus","enrollment":127},{"nctId":"NCT06174688","phase":"PHASE3","title":"A Study to Assess the Adverse Events and Effectiveness of BOTOX Injections for the Treatment of Moderate to Severe Forehead Lines in Chinese Adult Participants","status":"COMPLETED","sponsor":"AbbVie","startDate":"2023-12-12","conditions":"Forehead Lines","enrollment":140},{"nctId":"NCT05565950","phase":"PHASE1, PHASE2","title":"AI-09 In Subjects With Glabellar Lines, GL-101","status":"COMPLETED","sponsor":"Eirion Therapeutics Inc.","startDate":"2022-09-03","conditions":"Glabellar Frown Lines","enrollment":72},{"nctId":"NCT06137287","phase":"PHASE3","title":"A Study to Assess Adverse Events and Change of Masseter Muscle Prominence Using BOTOX Injections in Adult Participants","status":"COMPLETED","sponsor":"AbbVie","startDate":"2023-11-22","conditions":"Masseter Muscle Prominence","enrollment":259},{"nctId":"NCT06794866","phase":"PHASE3","title":"A Study to Assess Adverse Events and Effectiveness of OnabotulinumtoxinA Intramuscular Injections for the Change of Moderate to Severe Forehead Lines in Adult Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2025-01-22","conditions":"Forehead Lines","enrollment":150},{"nctId":"NCT06150729","phase":"","title":"Study of Intramuscular Injections of OnabotulinumtoxinA to Assess Change in Disease Activity in Pediatric Participants With Spasticity Associated With Cerebral Palsy","status":"COMPLETED","sponsor":"AbbVie","startDate":"2023-09-08","conditions":"Spasticity","enrollment":107},{"nctId":"NCT05013424","phase":"PHASE2","title":"A Study of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines","status":"COMPLETED","sponsor":"Allergan","startDate":"2021-09-01","conditions":"Glabellar Lines","enrollment":92},{"nctId":"NCT07013279","phase":"PHASE3","title":"Evaluate the Efficacy and Safety of DWP712 With Moderate to Severe Glabellar Lines","status":"NOT_YET_RECRUITING","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2025-07-15","conditions":"Glabellar Lines","enrollment":324},{"nctId":"NCT04073303","phase":"PHASE3","title":"BOTOX® Treatment for Adults With a Wide Lower Face Due to Masseter Muscle Prominence","status":"COMPLETED","sponsor":"AbbVie","startDate":"2019-08-29","conditions":"Masseter Muscle Prominence","enrollment":377},{"nctId":"NCT04970407","phase":"PHASE1","title":"A Comparative Study to Evaluate the Effects and Mechanism of Action of Dysport®, Botox® and Xeomin® in the Extensor Digitorum Brevis Model in Healthy Adult Male Participants","status":"COMPLETED","sponsor":"Ipsen","startDate":"2021-07-06","conditions":"Healthy Participants","enrollment":45},{"nctId":"NCT06796855","phase":"PHASE4","title":"Comparing Treatments for Refractory Overactive Bladder: Bladder Denervation vs Botulinum Toxin Injections","status":"COMPLETED","sponsor":"Bagcilar Training and Research Hospital","startDate":"2023-02-01","conditions":"Overactive Bladder Syndrome, Refractory Overactive Bladder","enrollment":60},{"nctId":"NCT02969356","phase":"PHASE4","title":"Study to Evaluate Effects of DYSPORT® Injected in Lower and Upper Limb Combined With Guided Self-Rehabilitation Contract (GSC)","status":"COMPLETED","sponsor":"Ipsen","startDate":"2016-12-18","conditions":"Spastic Hemiparesis","enrollment":157},{"nctId":"NCT06824324","phase":"PHASE1, PHASE2","title":"The Use of Botulinum Toxin in the Management of Myofascial Pain Syndrome","status":"COMPLETED","sponsor":"Yassir R. Al-khannaq","startDate":"2024-03-12","conditions":"Myofacial Pain Syndrome","enrollment":14},{"nctId":"NCT06778421","phase":"PHASE1","title":"Impact of OnabotulinumtoxinA (BOTOX®) on Stress","status":"RECRUITING","sponsor":"Center for Advanced Facial Plastic Surgery","startDate":"2025-01-20","conditions":"Stress (Psychology), Stress, Healthy Adult Female Participants","enrollment":20},{"nctId":"NCT06633445","phase":"NA","title":"Injecting Lateral Pterygoid Muscle by Botulinum Toxin Type A With 2 Different Methods : 3D Guided Appliance and Electromyography (EMG) .","status":"COMPLETED","sponsor":"Mahmoud Akram Khodir","startDate":"2023-11-01","conditions":"Anterior Disc Displacement","enrollment":20},{"nctId":"NCT05134649","phase":"PHASE3","title":"A Study To Assess the Safety of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence","status":"COMPLETED","sponsor":"AbbVie","startDate":"2021-11-16","conditions":"Platysma Prominence","enrollment":292},{"nctId":"NCT04949399","phase":"PHASE3","title":"A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Moderate to Severe Platysma Prominence","status":"COMPLETED","sponsor":"AbbVie","startDate":"2021-07-08","conditions":"Platysma Prominence","enrollment":408},{"nctId":"NCT06677216","phase":"","title":"Botulinum Toxin in the Management of Temporo-mandibular Related Myalgia: a Prospective Study","status":"ENROLLING_BY_INVITATION","sponsor":"Diakonessenhuis, Utrecht","startDate":"2024-01-26","conditions":"TMD/Orofacial Pain, Myalgia of Mastication Muscle, Botulinum Toxin, Type a","enrollment":30},{"nctId":"NCT03783572","phase":"NA","title":"Upper-limb Active Function and Botulinum Toxin a","status":"RECRUITING","sponsor":"University Hospital, Toulouse","startDate":"2020-12-08","conditions":"Stroke, Muscle Spasticity, Upper Extremity Paralysis","enrollment":80},{"nctId":"NCT05016661","phase":"PHASE2","title":"Extension Study of ABP-20001 to Evaluate Safety and Efficacy of Repeat Treatments of ABP-450 for Migraine Prevention","status":"TERMINATED","sponsor":"AEON Biopharma, Inc.","startDate":"2021-10-19","conditions":"Migraine","enrollment":466},{"nctId":"NCT04900324","phase":"NA","title":"Intramuscular Injections of Botulinum Toxin in Lateral Pterygoid Muscle in the Treatment of Temporomandibular Dysfunctions: Studying the Interest of MRI Guidance and Ultrasound Guidance","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2021-09-13","conditions":"Mandibular Dysfunction","enrollment":4},{"nctId":"NCT06583551","phase":"NA","title":"Effectiveness of Botox, Dry Needling, Pharmacological Treatment, and Manual Therapy for Bruxism-Induced Myalgia","status":"COMPLETED","sponsor":"Saglik Bilimleri Universitesi","startDate":"2021-01-03","conditions":"Myalgia, Bruxism, Quality of Life","enrollment":80},{"nctId":"NCT04845178","phase":"PHASE2","title":"Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in Adults","status":"COMPLETED","sponsor":"AEON Biopharma, Inc.","startDate":"2021-03-01","conditions":"Migraine","enrollment":797},{"nctId":"NCT06569563","phase":"","title":"Innervation Characteristics and Determination of Nerve Entry Points of the Musculus Semispinalis Capitis","status":"COMPLETED","sponsor":"Medipol University","startDate":"2018-08-01","conditions":"Peripheral Nerve Disease, Muscular Injury","enrollment":20},{"nctId":"NCT04871451","phase":"PHASE2","title":"Extension Study of ABP-19000 to Evaluate Safety and Efficacy of Repeat Treatments of ABP-450 in Cervical Dystonia","status":"COMPLETED","sponsor":"AEON Biopharma, Inc.","startDate":"2021-07-27","conditions":"Cervical Dystonia","enrollment":51},{"nctId":"NCT04994535","phase":"PHASE3","title":"A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence","status":"COMPLETED","sponsor":"AbbVie","startDate":"2021-08-10","conditions":"Platysma Prominence","enrollment":426},{"nctId":"NCT06556030","phase":"PHASE4","title":"A Multicentre, Randomised, Single-blind, Controlled Protocol to Evaluate the Efficacy of Early Administration of Botulinum Toxin for Primary Midline Closure in Patients With Open Abdomen.","status":"NOT_YET_RECRUITING","sponsor":"Instituto de Investigación Hospital Universitario La Paz","startDate":"2025-01","conditions":"Botulinum Toxin Type A, Open Abdomen, Abdominal Wall","enrollment":50},{"nctId":"NCT05956509","phase":"PHASE1","title":"Study of Intramuscular Injections of ABBV-950 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Spasticity","status":"TERMINATED","sponsor":"AbbVie","startDate":"2024-01-12","conditions":"Upper Limb Spasticity","enrollment":1},{"nctId":"NCT05284019","phase":"PHASE4","title":"Real World Effectiveness of Eptinezumab in Participants With Migraine","status":"TERMINATED","sponsor":"H. Lundbeck A/S","startDate":"2022-03-04","conditions":"Migraine","enrollment":32},{"nctId":"NCT05606757","phase":"PHASE2","title":"A Study to Evaluate Adverse Events and Effectiveness of OnabotulinumtoxinA in Participants Undergoing Open Abdominal Ventral Hernia Repair for the Achievement of Primary Fascial Closure Without the Use of Component Separation Technique","status":"WITHDRAWN","sponsor":"AbbVie","startDate":"2024-05-07","conditions":"Ventral Hernia, Abdominal Hernia","enrollment":""},{"nctId":"NCT04766723","phase":"PHASE2","title":"A Study to Investigate the Efficacy and Safety of NT 201 (Botulinum Toxin) Compared With Placebo for the Treatment of Adult Participants With Essential Tremor in the Arm","status":"COMPLETED","sponsor":"Merz Pharmaceuticals GmbH","startDate":"2021-02-24","conditions":"Essential Tremor of the Upper Limb","enrollment":78},{"nctId":"NCT01485601","phase":"PHASE2","title":"Safety and Efficacy Study of Botulinum Toxin Type A to Treat Glabellar Lines","status":"COMPLETED","sponsor":"Medy-Tox","startDate":"2011-12-07","conditions":"Glabellar Frown Lines","enrollment":121},{"nctId":"NCT05277337","phase":"PHASE4","title":"Study Comparing Treatment With Alluzience vs Reconstituted Toxin","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2022-02-04","conditions":"Glabellar Frown Lines","enrollment":150},{"nctId":"NCT04849988","phase":"PHASE2","title":"A Phase 2 Study to Evaluate the Safety and Efficacy of ABP-450 in the Treatment of Cervical Dystonia","status":"COMPLETED","sponsor":"AEON Biopharma, Inc.","startDate":"2021-03-29","conditions":"Cervical Dystonia","enrollment":61},{"nctId":"NCT05804656","phase":"PHASE3","title":"Efficacy and Safety of CKDB-501A in Subjects With Moderate-to-severe Glabellar Lines in Phase 3 Trial","status":"COMPLETED","sponsor":"CKD Bio Corporation","startDate":"2023-04-13","conditions":"Glabellar Lines","enrollment":300},{"nctId":"NCT04432285","phase":"","title":"Long-term Outcome of DBS Versus Botulinum Toxin Treatment in Cervical Dystonia","status":"UNKNOWN","sponsor":"Oslo University Hospital","startDate":"2020-08-06","conditions":"Cervical Dystonia","enrollment":50},{"nctId":"NCT03806933","phase":"PHASE2","title":"Study to Investigate the Safety and Duration of Effect of Different Botulinum Toxin A (NT 201) Dose Groups Following the Treatment of Glabellar Frown Lines","status":"COMPLETED","sponsor":"Merz Aesthetics GmbH","startDate":"2019-01-23","conditions":"Moderate to Severe Glabellar Frown Lines","enrollment":241},{"nctId":"NCT05463965","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of QM1114-DP for the Treatment of Moderate to Severe Glabellar Lines","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2022-07-29","conditions":"Moderate to Severe Glabellar Lines","enrollment":605},{"nctId":"NCT03380559","phase":"PHASE3","title":"A Phase III Study to Evaluate Efficacy of Botulinum Toxin for Treating Epicondylitis","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2019-04-19","conditions":"Epicondylitis","enrollment":33},{"nctId":"NCT03137407","phase":"PHASE2","title":"Phase 2 DaxibotulinumtoxinA for Injection for the Management of Plantar Fasciitis","status":"COMPLETED","sponsor":"Revance Therapeutics, Inc.","startDate":"2017-06-12","conditions":"Plantar Fasciitis","enrollment":59},{"nctId":"NCT04247074","phase":"PHASE3","title":"Treatment of Moderate to Severe Lateral Canthal Lines and Glabellar Lines Alone or in Combination","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2020-02-10","conditions":"Glabellar Frown Lines (GL), Lateral Canthal Lines (LCL)","enrollment":413},{"nctId":"NCT04544280","phase":"NA","title":"Effect of Repeated Injections of Higher Doses of Botulinum Toxin on Lower Limb of Spastic Hemiplegic Patients on Gait.","status":"COMPLETED","sponsor":"Cliniques universitaires Saint-Luc- Université Catholique de Louvain","startDate":"2018-09-13","conditions":"Stroke","enrollment":32},{"nctId":"NCT05298449","phase":"PHASE2","title":"Phase 2 of HU-045 in Glabellar Lines","status":"COMPLETED","sponsor":"Huons Co., Ltd.","startDate":"2022-03-28","conditions":"Glabellar Lines","enrollment":50},{"nctId":"NCT02088632","phase":"PHASE2","title":"Incobotulinum Toxin for the Treatment of Trigeminal Neuralgia","status":"TERMINATED","sponsor":"Thomas Jefferson University","startDate":"2014-03-14","conditions":"Trigeminal Neuralgia","enrollment":6},{"nctId":"NCT03911102","phase":"PHASE2","title":"Efficacy and Safety of Increasing Doses of DaxibotulinumtoxinA for Injection (DAXI for Injection) in the Treatment of Moderate or Severe Lateral Canthal Lines","status":"COMPLETED","sponsor":"Revance Therapeutics, Inc.","startDate":"2019-03-11","conditions":"Lateral Canthal Lines","enrollment":63},{"nctId":"NCT04259086","phase":"PHASE2","title":"Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for Treatment of Upper Facial Lines","status":"COMPLETED","sponsor":"Revance Therapeutics, Inc.","startDate":"2019-12-06","conditions":"Upper Facial Lines (Glabellar Lines, Forehead Lines, & Lateral Canthal Lines)","enrollment":48},{"nctId":"NCT04249583","phase":"PHASE3","title":"Treatment of Moderate to Severe Glabellar Lines","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2020-02-10","conditions":"Glabellar Frown Lines","enrollment":300},{"nctId":"NCT04249687","phase":"PHASE3","title":"Treatment of Moderate to Severe Lateral Canthal Lines","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2020-02-10","conditions":"Lateral Canthal Lines","enrollment":303},{"nctId":"NCT05496335","phase":"PHASE1","title":"A Study to Evaluate Sequential Administration of AGN-151586 and OnabotulinumtoxinA (BOTOX) Injections in Adult Participants for Treatment of Glabellar Lines","status":"COMPLETED","sponsor":"AbbVie","startDate":"2022-08-30","conditions":"Glabellar Lines","enrollment":90},{"nctId":"NCT03915067","phase":"PHASE2","title":"BOTOX® for the Treatment of Platysma Prominence","status":"COMPLETED","sponsor":"Allergan","startDate":"2019-04-23","conditions":"Platysma Prominence","enrollment":171},{"nctId":"NCT05840445","phase":"PHASE4","title":"Efficacy of Prabotulinum and Onabotulinum Toxin-A for Facial Wrinkles","status":"COMPLETED","sponsor":"Instituto de Oftalmología Fundación Conde de Valenciana","startDate":"2020-06-15","conditions":"Face, Skin Fold, Rejuvenation","enrollment":26},{"nctId":"NCT03701919","phase":"PHASE4","title":"Botulinum Toxin Pyloroplasty to Reduce Postoperative Nausea and Vomiting After Sleeve Gastrectomy","status":"COMPLETED","sponsor":"Albany Medical College","startDate":"2019-01-07","conditions":"Bariatric Surgery, Postoperative Nausea and Vomiting","enrollment":84},{"nctId":"NCT04815967","phase":"PHASE2, PHASE3","title":"Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity","status":"UNKNOWN","sponsor":"Supernus Pharmaceuticals, Inc.","startDate":"2021-11-16","conditions":"Spasticity, Cerebrovascular Accident, Multiple Sclerosis","enrollment":272},{"nctId":"NCT04099667","phase":"PHASE2, PHASE3","title":"Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Lower Limb Spasticity","status":"UNKNOWN","sponsor":"Supernus Pharmaceuticals, Inc.","startDate":"2019-12-17","conditions":"Spasticity","enrollment":272},{"nctId":"NCT03786770","phase":"PHASE2","title":"Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for Treatment of Forehead Lines (Frontalis)","status":"COMPLETED","sponsor":"Revance Therapeutics, Inc.","startDate":"2019-01-24","conditions":"Frown Lines","enrollment":61},{"nctId":"NCT03223298","phase":"PHASE3","title":"Botulinum Toxin Versus Placebo Injections to Temporalis and Masseter Muscles","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2018-08-31","conditions":"Pain, Head, Pain Syndrome, Temporomandibular Disorder","enrollment":75},{"nctId":"NCT05691556","phase":"","title":"Study of the Sensitivity to Change of a Bimanual 3D Analysis Protocol for the Assessment of Upper Limb Movement in Children With Cerebral Palsy Before and After Therapies","status":"UNKNOWN","sponsor":"University Hospital, Brest","startDate":"2020-07-16","conditions":"Cerebral Palsy Infantile","enrollment":20},{"nctId":"NCT05651256","phase":"PHASE2, PHASE3","title":"Efficacy of Botulinum Toxin in Temporomandibular Disorders","status":"COMPLETED","sponsor":"University of Salamanca","startDate":"2021-03-01","conditions":"Temporomandibular Joint Disorder Bilateral","enrollment":20},{"nctId":"NCT05292638","phase":"PHASE1","title":"Safety and Efficacy of CKDB-501A in Subjects With Moderate-to-severe Glabellar Lines","status":"COMPLETED","sponsor":"CKD Bio Corporation","startDate":"2022-02-15","conditions":"Glabellar Lines","enrollment":30},{"nctId":"NCT01251380","phase":"PHASE3","title":"Dysport® Pediatric Lower Limb Spasticity Follow-on Study","status":"COMPLETED","sponsor":"Ipsen","startDate":"2011-10","conditions":"Cerebral Palsy, Muscle Spasticity, Children","enrollment":216},{"nctId":"NCT02353871","phase":"PHASE3","title":"Efficacy and Safety of Clostridium Botulinum Toxin Type A to Improve Appearance of Moderate to Severe Glabellar Lines","status":"COMPLETED","sponsor":"Ipsen","startDate":"2015-01","conditions":"Moderate to Severe Glabellar Lines","enrollment":185},{"nctId":"NCT01251367","phase":"PHASE3","title":"Dysport® Adult Lower Limb Spasticity Follow-on Study","status":"COMPLETED","sponsor":"Ipsen","startDate":"2011-06","conditions":"Post-stroke Spasticity, Spasticity Post-Traumatic Brain Injury","enrollment":352},{"nctId":"NCT01313299","phase":"PHASE3","title":"Dysport® Adult Upper Limb Spasticity","status":"COMPLETED","sponsor":"Ipsen","startDate":"2011-08","conditions":"Nervous System Disorders","enrollment":243},{"nctId":"NCT00288509","phase":"PHASE3","title":"Open-label Extension Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia","status":"COMPLETED","sponsor":"Ipsen","startDate":"2006-02","conditions":"Cervical Dystonia","enrollment":108},{"nctId":"NCT02321436","phase":"PHASE4","title":"Study to Assess Impact of Dysport Injections Early After Stroke on Upper Limb Spasticity Progression","status":"COMPLETED","sponsor":"Ipsen","startDate":"2014-12","conditions":"Stroke, Upper Limb Spasticity","enrollment":42},{"nctId":"NCT01313312","phase":"PHASE3","title":"Dysport® Adult Upper Limb Spasticity Extension Study","status":"COMPLETED","sponsor":"Ipsen","startDate":"2011-11","conditions":"Nervous System Disorders","enrollment":258},{"nctId":"NCT01261611","phase":"PHASE3","title":"Study Comparing Short Term Efficacy of Dysport and Dysport NG to Placebo, and to Assess Efficacy and Safety of Dysport NG of Subjects With Cervical Dystonia","status":"COMPLETED","sponsor":"Ipsen","startDate":"2011-04","conditions":"Cervical Dystonia","enrollment":382},{"nctId":"NCT05517538","phase":"NA","title":"Split-face Study: Cosmetic Botulinum Toxin Type A Injection Under Electromyography-guidance Versus Conventional Palpation Technique","status":"COMPLETED","sponsor":"Mohamed Hayder Oleish Salih","startDate":"2021-08-09","conditions":"Glabellar Frown Lines, Rhytides, Wrinkle","enrollment":15},{"nctId":"NCT03014622","phase":"PHASE3","title":"Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines","status":"COMPLETED","sponsor":"Revance Therapeutics, Inc.","startDate":"2016-12-08","conditions":"Glabellar Frown Lines","enrollment":303},{"nctId":"NCT03014635","phase":"PHASE3","title":"Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines","status":"COMPLETED","sponsor":"Revance Therapeutics, Inc.","startDate":"2016-12-05","conditions":"Glabellar Frown Lines","enrollment":306},{"nctId":"NCT03004248","phase":"PHASE3","title":"Safety of Single and Repeat Treatments of DaxibotulinumtoxinA for Injection for Treatment of Moderate to Severe Glabellar Lines","status":"COMPLETED","sponsor":"Revance Therapeutics, Inc.","startDate":"2016-12-09","conditions":"Glabellar Frown Lines","enrollment":2691},{"nctId":"NCT01459666","phase":"PHASE4","title":"Forehead Scars Following Mohs Micrographic Surgery and Reconstruction for Skin Cancer","status":"TERMINATED","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2011-09","conditions":"Scar","enrollment":9},{"nctId":"NCT05162300","phase":"PHASE4","title":"Same-Day Combination of VI Peel and Botox for Correction of Sun Damage, Fine Lines and Wrinkles","status":"COMPLETED","sponsor":"Vitality Institute Medical Products","startDate":"2021-12-08","conditions":"Photoaging, Wrinkle, Sun Damaged Skin","enrollment":30},{"nctId":"NCT03855046","phase":"PHASE4","title":"Complex Treatment of a Chronic Anal Fissure","status":"RECRUITING","sponsor":"State Scientific Centre of Coloproctology, Russian Federation","startDate":"2019-09-01","conditions":"Fissure in Ano","enrollment":340},{"nctId":"NCT02546999","phase":"PHASE4","title":"Does Botulinum Toxin A Make Walking Easier in Children With Cerebral Palsy?","status":"COMPLETED","sponsor":"St. Olavs Hospital","startDate":"2015-09","conditions":"Cerebral Palsy, Muscle Spasticity","enrollment":61},{"nctId":"NCT03598777","phase":"PHASE2","title":"Dysport in Vulvodynia Phase II Study","status":"TERMINATED","sponsor":"Ipsen","startDate":"2018-06-11","conditions":"Vulvodynia","enrollment":60},{"nctId":"NCT04582929","phase":"PHASE3","title":"Neubotulinum Toxin Injection in Cerivical Dystonia","status":"COMPLETED","sponsor":"Department of Medical Services Ministry of Public Health of Thailand","startDate":"2019-01-03","conditions":"Cervical Dystonia","enrollment":50},{"nctId":"NCT01893411","phase":"PHASE3","title":"Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Leg(s) in Cerebral Palsy","status":"COMPLETED","sponsor":"Merz Pharmaceuticals GmbH","startDate":"2013-06","conditions":"Lower Limb Spasticity Due to Cerebral Palsy","enrollment":311},{"nctId":"NCT02002884","phase":"PHASE3","title":"Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Arm(s) or of Arm(s) and Leg(s) in Cerebral Palsy","status":"COMPLETED","sponsor":"Merz Pharmaceuticals GmbH","startDate":"2014-03-28","conditions":"Cerebral Palsy, Spasticity","enrollment":351}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":271,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Botox, Allergan."],"phase":"phase_3","status":"active","brandName":"botulinum toxin intramuscular injection","genericName":"botulinum toxin intramuscular injection","companyName":"Guy's and St Thomas' NHS Foundation Trust","companyId":"guy-s-and-st-thomas-nhs-foundation-trust","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Botulinum toxin works by blocking the release of acetylcholine, a neurotransmitter that transmits nerve impulses, thereby reducing muscle spasms and contractions. Used for Treatment of blepharospasm, hemifacial spasm, and strabismus, Treatment of cervical dystonia, Treatment of axillary hyperhidrosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}